Corporate Update on Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) reported a 4.82 % rise in its share price during the 24‑hour period concluding at 10:03 PM Central Europe on Wednesday, 21 November 2026. At the close, one share was trading at approximately USD 0.50 on major exchanges. The company’s market capitalization stands at USD 15.9 million, derived from a circulating supply of 33.3 million shares. In the preceding 24 hours, trading volume totaled roughly USD 183.3 k.
Recent Performance Metrics
- Current Share Price: USD 0.50
- Market Capitalization: USD 15.9 million
- Trading Volume (24 hrs): USD 183.3 k
- Year‑to‑Date Return: –17.08 % since the end of October 2026
- 200‑Day Simple Moving Average: USD 0.90
- 52‑Week High: USD 2.52 (29 October 2025)
- 52‑Week Low: USD 0.32 (29 June 2026)
These figures illustrate a company that remains highly volatile yet is poised for strategic moves that could reshape its valuation trajectory.
Upcoming Shareholder Meeting
Jasper Therapeutics is convening a virtual special meeting of shareholders on 13 November 2026. The agenda will cover several critical matters linked to the company’s recent acquisition of Kira Pharmaceuticals and a private placement financing. Key items include:
- Conversion of Preferred Stock into Common Shares
- Approval sought to convert the company’s preferred shares in accordance with Nasdaq listing rules.
- Conversion of Newly Issued Preferred Shares
- Shareholders will consider whether the preferred shares issued through the private placement should be converted.
- Ratification of a New Board Director
- A nomination will be presented for board approval, ensuring governance alignment with strategic objectives.
- Adjournment Provision
- If adequate votes are not obtained, the board may adjourn the meeting to a later date.
- Reverse Stock Split
- The company has announced plans for a reverse split, though the exact ratio remains undetermined. This action could enhance liquidity and align the stock price more closely with Nasdaq’s minimum price requirements.
Voting will take place online or by proxy, and the board has recommended a “for” vote on all proposals. The outcomes will dictate the number of common shares that may be issued and confirm Jasper’s compliance with Nasdaq’s listing mandates.
Comparative Market Context
In the past 24 hours, several peer stocks have exhibited varied performance:
| Stock | Ticker | % Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Quanome | QNME | –11.57 % | 0.48 | 18.4 million |
| Ai Okto | AIOK | +23.87 % | 4.84 | 18.1 million |
| Snail | SNAL | –2.9 % | 2.28 | 18.5 million |
| American Strategic Investment | NYC | +3.56 % | 5.86 | 18.2 million |
| Spar | SGRP | 0 % | 0.68 | 18.5 million |
Ai Okto’s recent filing of a shelf registration statement (Form F‑3) on 20 October 2026 indicates a potential for significant capital raising, which may influence market sentiment across the biotechnology and shipping sectors. Jasper Therapeutics, by contrast, remains focused on regenerative medicine, with a strategic emphasis on safer stem‑cell and gene‑therapy environments.
Company Profile
Jasper Therapeutics, Inc. is a global biotechnology firm dedicated to creating safer conditions for curative therapy applications involving stem cell transplants and gene therapies. By concentrating on this niche, the company seeks to transform the healthcare landscape, making advanced regenerative treatments more accessible and effective worldwide. Their research and development pipeline aims to address unmet clinical needs, positioning Jasper as a potential leader in the evolving field of regenerative medicine.
This article synthesizes the latest corporate developments and market data for Jasper Therapeutics, providing stakeholders with a concise yet comprehensive overview of the company’s current standing and forthcoming strategic decisions.
